Cancer survival time prediction using Deep Learning (DL) has been an emerging area of research. However, non-availability of large-sized annotated medical imaging databases affects the training performance of DL models leading to their arguable usage in many clinical applications. In this research work, a neural network model is customized for small sample space to avoid data over-fitting for DL training. A set of prognostic radiomic features is selected through an iterative process using average of multiple dropouts which results in back-propagated gradients with low variance, thus increasing the network learning capability, reliable feature selection and better training over a small database. The proposed classifier is further compared with erasing feature selection method proposed in the literature for improved network training and with other well-known classifiers on small sample size. Achieved results which were statistically validated show efficient and improved classification of cancer survival time into three intervals of 6 months, between 6 months up to 2 years, and above 2 years; and has the potential to aid health care professionals in lung tumor evaluation for timely treatment and patient care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.compbiomed.2023.106896 | DOI Listing |
Clin Lung Cancer
December 2024
Department of Thoracic Surgery, Liverpool Heart and Lung Hospital, Liverpool, UK.
Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.
Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.
Clin Lung Cancer
December 2024
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Objective: To determine the association between concurrent statin use with immune checkpoint inhibitors (ICIs) and lung cancer-specific and overall mortality in patients with nonsmall cell lung cancer (NSCLC).
Materials And Methods: SEER-Medicare was used to conduct a retrospective study of Medicare beneficiaries ≥65 years of age diagnosed with NSCLC between 2007 and 2017 treated with an ICI. Patients were followed from date of first ICI claim until death, 1 month from last ICI claim, or 12/31/2018, whichever came first.
Blood Rev
January 2025
Department of Hematology, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address:
Multiple myeloma (MM) remains incurable and patients eventually face the relapse/refractory dilemma. B cell maturation antigen (BCMA)-targeted immunotherapeutic approaches have shown great effectiveness in patients with relapsed/refractory MM, mainly including chimeric antigen receptor T cells (CAR-T), bispecific T cell engagers (TCEs), and antibody-drug conjugates (ADCs). However, their impact on long-term survival remains to be determined.
View Article and Find Full Text PDFSurgery
January 2025
Department of Oncology, The First Hospital of Hohhot, Hohhot, China. Electronic address:
Clin Colorectal Cancer
December 2024
Medical University Vienna, Department of Medicine I, Vienna, Austria. Electronic address:
Background: The efficacy of trifluridine/tipiracil (FTD/TPI) + bevacizumab compared to FTD/TPI for treatment of refractory metastatic colorectal cancer (mCRC) was demonstrated in the SUNLIGHT trial. This analysis of SUNLIGHT investigated the impact of treatment with FTD/TPI + bevacizumab on patient quality of life (QoL) and Eastern Cooperative Oncology Group performance status (ECOG PS).
Methods: Questionnaires (EORTC QLQ-C30 and EQ-5D-5L) and ECOG PS assessments were conducted at baseline and on Day 1 of each treatment cycle.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!